Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 3, 2009, Pages 893-899

  Mansfield, Kylie J ^a,b   Chandran, Jonathan J ^a   Vaux, Kenneth J ^c   Millard, Richard J ^d   Christopoulos, Arthur ^e   Mitchelson, Frederick J ^f   Burcher, Elizabeth ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c SYDNEY ADVENTIST HOSPITAL   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINYL BENZILATE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE; UK 148993; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; BLADDER MUCOSA; CHO CELL; CONTROLLED STUDY; DETRUSOR MUSCLE; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; HUMAN TISSUE; LIGAND BINDING; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL;

AGED; BENZHYDRYL COMPOUNDS; BENZOFURANS; CRESOLS; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; PROSTATECTOMY; PYRROLIDINES; QUINUCLIDINES; QUINUCLIDINYL BENZILATE; RADIOLIGAND ASSAY; RECEPTORS, MUSCARINIC; TETRAHYDROISOQUINOLINES; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 62449273471     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.145508     Document Type: Article

References (37)

1. Abrams P and Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987-1006.
2. Andersson KE and Yoshida M (2003) Antimuscarinics and the overactive detrusor-Which is the main mechanism of action? Eur Urol 43:1-5.
3. Brubaker L (2004) Urgency: the cornerstone symptom of overactive bladder. Urology 64:12-16.
4. Bschleipfer T, Schukowski K, Weidner W, Grando SA, Schwantes U, Knmmer W, and Lips KS (2007) Expression and distribution of cholinergic receptors in the human urothelium. Life Sci 80:2303-2307.
5. Chappie CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, and Ridder A (2004) Randomised, double-blind placebo-and tolterodme-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303-310.
6. Colli E, Digesu GA, and Olivieri L (2007) Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs 16:999-1007.
7. D'Agostmo G. Bolognesi ML. Lucchelli A, Vicini D, Balestra B, Spelta V, Melchiorre C, and Tonini M (2000) Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor: involvement of M4 receptor subtype. Br J Pharmacol 129:493-500.
8. De Laet K, De Wachter S, and Wyndaele JJ (2006) Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 25:156-161.
9. De Wachter S and Wyndaele JJ (2003) Intravesical oxybutynin: a local anaesthetic effect on bladder C afferents. J Urol 169:1892-1895.
10. Enzelsberger H, Helmer H, and Kurz C (1995) Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial. Br J Obstet Gynaecol 102:929-930.
11. Ferguson DR, Kennedy I, and Burton TJ (1997) ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes-a possible sensory mechanism? J Physiol 505:503-511.
12. Finney SM, Andersson KE, Gillespie JI, and Stewart LH (2006) Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 98:503-507.
13. Freeman R, Hill S, Millard R, Slack M, and Sutherst J (2003) Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 102:605-611.
14. Fröhlich G, Burmeister S, Wiedemann A, and Bulitta M (1998) Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomised clinical test. Arzneimittelforschung 48:486-491.
15. Fry CH, Ikeda Y, Harvey R, Wu C, and Sui GP (2004) Control of bladder function by peripheral nerves: avenues for novel drug targets. Urology 63:24-31.
16. Hanna-Mitchell AT, Beckel JM, Barbadora S, Kanai AJ, de Groat WC, and Birder LA (2007) Non-neuronal acetylcholine and urinary bladder urothelium. Life Sci 80:2298-2302.
17. Hegde SS (2006) Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147:S80-S87.
18. 3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 52:842-847.
19. Kim Y, Yoshimura N, Masuda H, de Miguel F, and Chancellor MB (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladderafferent pathways. Urology 65:238-242.
20. 4 muscarinic acetylcholine receptors. Mol Pharmacol 70:736-746.
21. Madersbacher H and Jilg G (1991) Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia 29:84-90.
22. Masuda H, Kim YT, Tyagi S, Chancellor MB, de Miguel F, and Yoshimura N (2006) Local effects of antimuscarinics. Urol Clin North Am 33:511-518, ix-x.
23. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, and Burcher E (2005) Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes with ageing. Br J Pharmacol 144:1089-1099.
24. 2 muscarinic acetylcholine receptors. Mol Pharmacol 72:463-476.
25. Millard RJ and Halaska M (2006) Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin 22:41-48.
26. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, and Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760-766.
27. Michel MC and Hegde SS (2006) Treatment of the OAB syndrome with muscarinic receptor antagonists: a matter of metabolites? Naunyn Schiniedebergs Arch Pharmacol 374:79-85.
28. 3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 176:367-373.
29. Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stöhr T, and Andersson KE (2008) Pharmacological characterisation of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int 101:1036-1042.
30. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, and Wein AJ (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327-336.
31. Tyagi S, Tyagi P, Van-le S, Yoshimura N, Chancellor MB, and de Miguel F (2006) Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol 176:1673-1678.
32. Wagg A, Wyndaele JJ, and Sieber P (2006) Efficacy and Tolerability of Solifenacin in Elderly Subjects with Overactive Bladder Syndrome: A Pooled Analysis. Am J Geriatr Pharmacother 4:14-24.
33. Walter P, Grosse J, Bihr AM, Kramer G, Schulz HU, Schwantes U, and Stöhrer M (1999) Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: a pilot study. Neurourol Urodyn 18:447-453.
34. Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, and Akino H (2005) Effects of tolterodine on an overactive bladder depend on suppression of C-fibre bladder afferent activity in rats. J Urol 174:2032-2036.
35. Yoshida M, Miyamae K, Iwashita H, Otani M, and Inadome A (2004) Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology 63:17-23.
36. Yoshida M, Inadome A, Maeda Y, Satoji Y, Masunaga K, Sugiyama Y, and Murakami S (2006) Non-neuronal cholinergic system in human bladder urothelium. Urology 67:425-430.
37. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, and Auerbach S (2004) Trospium chloride improves overactive bladder symptoms: a multicentre phase III trial. J Urol 171:2311-2315.